Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with MPSIIIA. Estudio de fase I/II para evaluar la seguridad, tolerabilidad y eficacia inicial del vector viral adenoasociado de serotipo 9 conteniendo el gen de la sulfamidasa humana tras su administración por vía intracerebroventricular a pacientes con MPSIIIA.

Next Previous
Trial Profile

Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with MPSIIIA. Estudio de fase I/II para evaluar la seguridad, tolerabilidad y eficacia inicial del vector viral adenoasociado de serotipo 9 conteniendo el gen de la sulfamidasa humana tras su administración por vía intracerebroventricular a pacientes con MPSIIIA.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EGT 101 (Primary)
  • Indications Mucopolysaccharidosis III
  • Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
  • Sponsors Esteve

Most Recent Events

  • 10 Jun 2016 Status changed from planning to recruiting.
  • 01 Mar 2016 New trial record
  • 25 Feb 2016 According to ESTEVE and UAB media release, company is planning to initiate this trial by the end of 2016. EGT-101 received orphan drug designation by the FDA and EMA in 2011.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top